Novo Nordisk reined in its growth forecasts for the year in its second-quarter financial results update, blaming "persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition." Compounding of semaglutide should have come to a halt in the US since the drug was removed from the FDA list of medicines in short supply, but various companies continue to provide compounded GLP-1s under a loophole that allows the sale of 'personalised' formulations
Future research should focus on developing strategies for selective targeting to minimize effects on normal tissues, understanding mechanisms of resistance and ways to overcome them, and optimizing combination therapies with chemotherapy, radiotherapy, or immunotherapy to enhance efficacy
Third Annual VA Oncology Conference
Look for official distributors or authorized retailers
As such, we conclude that rs10305420 is probably the causal variant